The authors validated the effects of tumour cells on LX-2 activation and GDF15 expression in a xenograft in vivo study and validated in 12 HCC patients that tumour-associated HSCs express higher levels of GDF15 than non-tumour HSCs [77]. The gene discussed is GDF15; the disease is hepatocellular carcinoma.